X-linked Adrenoleukodystrophy
1
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Minoryx TherapeuticsSpain - Barcelona
1 programDisease Progression in Women With X-linked AdrenoleukodystrophyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Oregon TherapeuticsSobetirome
Minoryx TherapeuticsDisease Progression in Women With X-linked Adrenoleukodystrophy
Clinical Trials (2)
Total enrollment: 40 patients across 2 trials
Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)
Start: Apr 2013Est. completion: Feb 20140
Phase 1Withdrawn
Disease Progression in Women With X-linked Adrenoleukodystrophy
Start: Jan 2024Est. completion: Jun 202740 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 40 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.